On the eve of a closely watched trial, Teva Pharmaceutical (TEVA) agreed to pay $85 million to settle charges made by the state of Oklahoma of fueling the opioid crisis by overstating the benefits of its opioid painkillers and downplaying addictive risks that led doctors to prescribe the drugs unnecessarily.

The agreement, which must still be finalized, was announced on Sunday, just two days before a trial is scheduled to get underway. However, Oklahoma Attorney General Mike Hunter said the trial will continue as planned against Johnson & Johnson (JNJ), which faces the same claims. Several weeks ago, Purdue Pharma agreed to pay $270 million to settle allegations by the state.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy